Abiopharma

🔍 Bohnen Shane (Executive)

Company: BIO-TECHNE Corp (TECH)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | shares_owned_after: 10,360.00
• Acquired 11,344 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,344.00 | transaction_form_type: 4 | Footnotes: F6, F11, F11
• Acquired 18,432 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 18,432.00 | transaction_form_type: 4 | Footnotes: F6, F12, F12
• Holds 8,944 shares of Stock Option (Right to Buy) at $66.97 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2027-08-05 | shares_owned_after: 8,944.00 | Footnotes: F1
• Holds 3,460 shares of Stock Option (Right to Buy) at $120.46 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2028-08-06 | shares_owned_after: 3,460.00 | Footnotes: F1
• Holds 3,508 shares of Stock Option (Right to Buy) at $94.52 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2029-08-15 | shares_owned_after: 3,508.00 | Footnotes: F1
• Holds 3,928 shares of Stock Option (Right to Buy) at $73.76 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2030-04-03 | shares_owned_after: 3,928.00 | Footnotes: F2
• Holds 807 shares of Stock Option (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2030-08-15 | shares_owned_after: 807.00 | Footnotes: F1
• Holds 16,302 shares of Stock Option (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2030-08-15 | shares_owned_after: 16,302.00 | Footnotes: F3
• Holds 13,488 shares of Stock Option (Right to Buy) at $74.91 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2034-08-15 | shares_owned_after: 13,488.00 | Footnotes: F4
• Holds 17,897 shares of Stock Option (Right to Buy) at $53.6 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2035-08-15 | shares_owned_after: 17,897.00 | Footnotes: F5
• Holds 13,992 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 13,992.00 | Footnotes: F6, F7, F7
• Holds 10,012 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 10,012.00 | Footnotes: F6, F8, F8
• Holds 1,669 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 1,669.00 | Footnotes: F6, F9, F9
• Holds 4,664 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 4,664.00 | Footnotes: F6, F10, F10

Footnotes:

• F1: Fully exercisable.
• F2: Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
• F3: Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
• F4: Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
• F5: Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
• F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
• F7: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F8: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F9: 1,669 restricted stock units vest on 8/15/2027.
• F10: 2,332 restricted stock units vest on each of 8/15/2027 and 8/15/2028.
• F11: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029.
• F12: 18,432 restricted stock units vest on 8/17/2029.